List of Excipients in Branded Drug IRINOTECAN HYDROCHLORIDE

Generic Drugs Containing IRINOTECAN HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	irinotecan hydrochloride	0143-9583	HYDROCHLORIC ACID
Hikma Pharmaceuticals USA Inc	irinotecan hydrochloride	0143-9583	LACTIC ACID
Hikma Pharmaceuticals USA Inc	irinotecan hydrochloride	0143-9583	SODIUM HYDROXIDE
Hikma Pharmaceuticals USA Inc	irinotecan hydrochloride	0143-9583	SORBITOL
Hikma Pharmaceuticals USA Inc	irinotecan hydrochloride	0143-9583	WATER
Hikma Pharmaceuticals USA Inc	irinotecan hydrochloride	0143-9702	HYDROCHLORIC ACID

What are the Most Frequently-Used Excipients in IRINOTECAN HYDROCHLORIDE?

# Of NDCs	Excipient
18	HYDROCHLORIC ACID
20	LACTIC ACID
20	SODIUM HYDROXIDE
20	SORBITOL
14	WATER

Irinotecan Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Irinotecan hydrochloride is an established topoisomerase I inhibitor with a mature generic injection market and a separate premium opportunity in liposomal delivery. The conventional formulation is relatively simple: irinotecan hydrochloride in an acidic aqueous vehicle containing sorbitol and lactic acid. The principal commercial opportunity is not a new conventional generic alone. It is differentiated delivery, improved stability, reduced preparation burden, lower infusion toxicity, and excipient systems that support long-term supply and regulatory protection.

What excipients are used in irinotecan hydrochloride injection?

The reference irinotecan hydrochloride injection uses an acidic aqueous formulation with sorbitol and lactic acid.

Product	Active ingredient	Principal excipients or formulation components	Delivery
Camptosar	Irinotecan hydrochloride trihydrate	Sorbitol, lactic acid, water for injection; pH adjustment with hydrochloric acid or sodium hydroxide	Intravenous infusion
Generic irinotecan injection	Irinotecan hydrochloride	Generally follows the reference formulation or an equivalent excipient system	Intravenous infusion
Onivyde	Irinotecan sucrosofate, liposomal	Lipid bilayer containing phospholipid and cholesterol components, sucrose octasulfate counterion, buffering and tonicity agents	Intravenous infusion

The Camptosar label identifies irinotecan hydrochloride trihydrate at 20 mg/mL, with sorbitol and lactic acid in an acidic solution. The low pH supports chemical stability and limits precipitation of the drug substance.[1]

Sorbitol functions primarily as a tonicity and formulation-support excipient. Lactic acid contributes to pH control and may influence the stability of irinotecan in solution. The formulation is administered after dilution and is not intended for direct bolus injection.[1]

The excipient system is commercially important because irinotecan is sensitive to pH, hydrolysis, precipitation, container interaction, and handling conditions. A generic developer that changes the vehicle must establish pharmaceutical equivalence, stability, compatibility, and comparable clinical performance.

How does irinotecan hydrochloride compare with liposomal irinotecan?

Conventional irinotecan hydrochloride is a low-cost aqueous injection. Liposomal irinotecan is a differentiated delivery product with a substantially more complex excipient and manufacturing profile.

Attribute	Conventional irinotecan hydrochloride	Liposomal irinotecan
Form	Molecular solution	Encapsulated drug-lipid product
Principal formulation challenge	pH, hydrolysis, precipitation, infusion compatibility	Encapsulation efficiency, particle size, leakage, lipid oxidation, release rate
Regulatory route	Generally ANDA for equivalent injection	Usually 505(b)(2) or full application depending on product design
Manufacturing barrier	Moderate	High
Excipient intellectual property	Limited but possible	Significant
Pricing profile	Generic or low-cost branded	Specialty oncology
Competitive risk	Multiple generic suppliers	Fewer technically capable competitors
Commercial differentiation	Stability, ready-to-use packaging, waste reduction	Pharmacokinetics, dosing convenience, safety, tumor exposure

Onivyde contains a liposomal form of irinotecan. The product uses a sucrose octasulfate-based loading system and lipid excipients to retain irinotecan in the liposome. Its commercial value depends on the delivery architecture, not simply on the active ingredient.[2]

This distinction creates two different commercial strategies:

1. A conventional injectable strategy focused on cost, supply reliability, packaging, and stability.
2. A specialty formulation strategy focused on liposomal delivery, pharmacokinetic differentiation, and patentable manufacturing controls.

What excipient strategies offer commercial opportunities?

The strongest opportunities are in formulation systems that solve operational problems in oncology pharmacies and infusion centers.

Ready-to-use or reduced-dilution formulations

A ready-to-use or concentrated irinotecan presentation could reduce pharmacy compounding steps, preparation time, and exposure risk. The product would need to maintain stability after withdrawal, dilution, and storage in common infusion containers.

Potential formulation targets include:

• Higher-concentration aqueous solutions
• Premixed infusion bags
• Extended in-use stability after dilution
• Reduced adsorption to bags and tubing
• Lower extractables and leachables risk
• Simplified cold-chain requirements

A higher concentration is not automatically advantageous. It can increase precipitation risk, viscosity, local irritation, and container compatibility concerns. Commercial value would depend on measurable workflow savings and a clear stability advantage.

Alternative tonicity systems

Sorbitol is established in the reference product, but alternative tonicity agents could create formulation and supply-chain differentiation. Candidate excipients may include sodium chloride, glucose, mannitol, glycerol, or combinations of these materials.

The main technical issues are:

• Compatibility with acidic pH
• Osmolality after dilution
• Drug stability
• Color formation
• Container closure interaction
• Infusion tolerability
• Regulatory acceptability of the excipient level

A formulation that removes sorbitol could appeal to hospitals seeking a different excipient profile, but the commercial case would require a clinically meaningful advantage. A simple substitution may be difficult to protect and may not justify a new regulatory pathway.

Buffer and pH-control systems

Irinotecan formulations require tight pH control. Lactic acid is used in the reference product, but alternative acid-buffer systems may support improved stability or manufacturing robustness.

Potential approaches include:

• Lactate-buffered systems
• Citrate or acetate systems
• Low-capacity buffers with controlled pH drift
• Dual-compartment presentations separating drug and buffer until use
• pH-modified formulations designed to reduce precipitation during dilution

The most defensible patent position would likely require a defined pH range, excipient concentration, stability result, and specific container or dilution condition. Broad claims to irinotecan in an acidic aqueous solution are likely to face prior-art and obviousness challenges.

Lyophilized irinotecan products

A lyophilized irinotecan presentation could address shelf-life, transportation, and global distribution. Bulking agents and stabilizers such as mannitol, trehalose, sucrose, or selected amino acids could be evaluated.

The commercial advantages would include:

• Reduced water-driven degradation
• Longer room-temperature stability
• Lower shipping burden
• Potential use in markets with weak cold-chain infrastructure

The disadvantages include reconstitution time, cake variability, vial fill complexity, particulate risk, and additional pharmacy handling. A lyophilized product would have to outperform the existing liquid injection on total cost and operational convenience.

Container and administration systems

Excipients cannot be evaluated separately from the container closure and administration set. Irinotecan products may interact with elastomeric components, plastic bags, tubing, filters, and transfer devices.

Commercially relevant development areas include:

• Low-sorption infusion sets
• Compatible cyclic olefin polymer or glass containers
• Ready-to-use polymer bags
• Closed-system transfer devices
• Dose-banded presentations
• Single-dose vial formats that reduce residual waste

Device and packaging claims can supplement formulation patents. They may also provide a practical barrier against substitution where the active ingredient and liquid composition are otherwise difficult to distinguish.

What patent strategies protect irinotecan excipient innovations?

Conventional irinotecan hydrochloride is a mature small-molecule product. The original composition-of-matter protection is no longer the primary commercial barrier. New value must come from formulation, process, delivery, or use claims.

Formulation patents

A formulation patent may cover:

• Irinotecan concentration
• pH range
• Sorbitol or alternative tonicity-agent concentration
• Acid or buffer identity
• Preservative-free composition
• Stability after dilution
• Container compatibility
• Storage temperature
• Particle or impurity limits

Narrow claims tied to demonstrated stability are more defensible than broad claims covering any aqueous irinotecan solution.

Liposomal composition patents

Liposomal irinotecan claims may cover:

• Lipid identity and molar ratios
• Phospholipid-to-drug ratio
• Cholesterol content
• Surface-modifying polymers
• Sucrose octasulfate loading
• Encapsulation efficiency
• Particle-size distribution
• Release profile
• Residual free-drug content

Manufacturing claims are particularly important because liposomal products are difficult to reproduce through simple active-ingredient substitution. Claims may address remote loading, temperature control, mixing sequence, extrusion, dialysis, purification, and storage conditions.

Method-of-use and dosing patents

Method claims may cover combination regimens, dosing intervals, patient selection, biomarker-defined populations, or use after progression on another therapy. Their commercial value depends on whether the labeled indication and prescribing instructions create practical infringement risk.

For conventional irinotecan, method-of-use protection is more likely to affect specific regimens than the broad use of the drug in colorectal or pancreatic cancer.

When does irinotecan hydrochloride lose exclusivity?

The conventional Camptosar product has long lost its principal exclusivity barriers in the United States. Generic irinotecan hydrochloride injections are marketed through the ANDA pathway, subject to pharmaceutical equivalence and bioequivalence requirements appropriate for an injectable product.[3]

The relevant exclusivity landscape is:

Protection category	Conventional irinotecan hydrochloride	Commercial effect
New chemical entity exclusivity	Expired	No current NCE barrier
Original composition patent	Expired	Does not block generic injection
Formulation patents	Product- and jurisdiction-specific	May affect non-equivalent formulations
Method-of-use patents	Potentially relevant for specific regimens	Can create carve-out or litigation issues
Orphan exclusivity	Depends on product and indication	Not a general barrier to all irinotecan use
Biosimilar exclusivity	Not applicable	Irinotecan is a small molecule
Liposomal product patents	Relevant to Onivyde-type products	May block direct substitution or require a different route

The exact market-entry analysis must distinguish conventional irinotecan hydrochloride injection from liposomal irinotecan. A generic aqueous injection does not automatically substitute for Onivyde, and a liposomal product may face patent and regulatory barriers that do not apply to conventional irinotecan.

What is the FDA regulatory status of irinotecan formulations?

Conventional irinotecan hydrochloride injection is generally an ANDA opportunity. A product that has the same active ingredient, dosage form, route, strength, and pharmaceutical equivalence can pursue abbreviated approval.

A materially modified product may require a 505(b)(2) application. This pathway is relevant for:

• New concentration
• New delivery system
• Liposomal formulation
• Alternative dosing presentation
• Extended stability or ready-to-use product
• New combination of excipients with a clinical advantage

The regulatory burden rises with formulation complexity. A conventional aqueous generic may rely heavily on CMC and comparative data. A liposomal product may require extensive characterization of particle size, encapsulation, release, lipid composition, impurities, and pharmacokinetics.

FDA’s Orange Book identifies approved drug products and listed patents for applicable products. Applicants should review the current listing for both the reference injectable and any liposomal irinotecan reference product before making a Paragraph IV or 505(b)(2) strategy.[4]

How many patents cover irinotecan hydrochloride products?

The number depends on the product and jurisdiction.

For conventional irinotecan hydrochloride injection, the active-ingredient patent estate is mature, and the main exposure is usually product-specific formulation, manufacturing, method-of-use, or packaging protection. For liposomal irinotecan, the relevant estate can include multiple patent families covering composition, loading chemistry, manufacturing, release characteristics, and therapeutic use.

A useful diligence structure is:

Patent layer	Conventional injection	Liposomal irinotecan
Active ingredient	Low current risk	Same active ingredient, but not sufficient to define product
Excipient composition	Moderate, usually narrow	High
Manufacturing process	Moderate	High
Delivery device	Moderate	Moderate to high
Method of use	Indication-specific	Indication- and regimen-specific
Trade secret exposure	Limited	High, particularly process controls

Patent strength should be assessed claim by claim. A formulation patent is stronger when it has a narrow, reproducible composition and a measurable technical result, such as reduced degradation or improved encapsulation. A process patent is stronger when competitors cannot readily perform the claimed sequence without infringing.

Which companies are challenging or competing with irinotecan products?

Competition exists at several levels:

• Generic manufacturers supplying conventional irinotecan hydrochloride injection
• Originator and specialty companies commercializing liposomal irinotecan
• Contract manufacturers with sterile injectable capacity
• Liposome technology companies offering formulation or manufacturing platforms
• Oncology companies developing irinotecan combinations or alternative delivery systems

The generic market is primarily price- and supply-driven. The liposomal market is differentiated by clinical data, physician adoption, reimbursement, and manufacturing capability.

A new entrant should not assume that an approved generic injection can compete directly with a liposomal product. Hospitals may use the products in different treatment settings, and payer policies may distinguish them by indication and clinical evidence.

What generic entry risks exist for irinotecan hydrochloride?

Paragraph IV challenges

A Paragraph IV filing can target listed patents for a reference product. The most relevant arguments may include:

• Patent expiration
• Noninfringement based on a different excipient system
• Invalidity for anticipation or obviousness
• Lack of written description or enablement
• Nonapplicability of the listed patent to the proposed product

For conventional irinotecan, a Paragraph IV strategy is likely to focus on any remaining formulation or method-of-use patents rather than the basic active ingredient.

Carve-outs and skinny labels

A generic applicant may seek approval with labeling that omits protected indications or dosing regimens. The commercial value of a carve-out depends on whether the unprotected indication is large enough to support launch.

In oncology, label carve-outs can be commercially complex because treatment regimens overlap in clinical practice. Marketing materials and physician communications must be reviewed for induced-infringement risk.

Liposomal substitution risk

The principal risk to a liposomal irinotecan product is not ordinary generic substitution. A competing applicant must usually demonstrate that its product has comparable delivery characteristics or establish a new clinical and regulatory basis.

Potential barriers include:

• Lipid composition differences
• Encapsulation variability
• Release-profile differences
• Pharmacokinetic divergence
• Manufacturing scale-up
• Sterility and particulate control
• Patent claims covering loading chemistry

What licensing opportunities exist in irinotecan excipients and delivery?

The most attractive licensing opportunities are likely to involve enabling technology rather than commodity excipients.

Potential deal targets include:

• Liposome loading platforms
• Sterile injectable manufacturing capacity
• Novel low-sorption packaging
• Extended-stability systems
• Closed-system transfer devices
• Novel excipients with established regulatory precedent
• Drug-excipient combinations with granted patents
• Regional rights for oncology injectables
• Co-development of 505(b)(2) delivery products

Commodity sorbitol, lactic acid, sodium chloride, and common buffers are unlikely to support substantial standalone licensing value. Their value increases when combined with a protected concentration range, stability profile, delivery device, or manufacturing process.

How strong is the patent estate for irinotecan excipient products?

The estate is weak for undifferentiated conventional injection products and stronger for complex delivery systems.

A conventional formulation based on the same active ingredient, similar pH, and common excipients may have limited patent differentiation. Its commercial defenses are more likely to be:

• Manufacturing cost
• Sterile capacity
• Supply reliability
• Contracting
• Packaging efficiency
• Regulatory execution

A liposomal or extended-stability product can support a stronger patent estate, but the claims must be supported by detailed CMC evidence. The most valuable protection will usually combine composition, process, product-performance, and use claims rather than rely on a single excipient claim.

Key Takeaways

• Conventional irinotecan hydrochloride injection uses an acidic aqueous system centered on sorbitol and lactic acid.
• The basic injectable market is mature and exposed to generic competition.
• The strongest commercial opportunity is differentiated delivery, particularly liposomal, ready-to-use, extended-stability, or waste-reducing products.
• Sorbitol or lactic acid substitution alone is unlikely to create durable value without a measurable stability, safety, or operational advantage.
• Liposomal irinotecan has higher technical, regulatory, manufacturing, and patent barriers than conventional injection.
• Irinotecan is a small molecule, so biosimilar analysis is not applicable.
• Paragraph IV exposure depends on current Orange Book listings and the specific reference product.
• The most defensible new patent claims will cover defined excipient ratios, pH ranges, stability results, loading processes, particle characteristics, packaging systems, or clinical use.
• Licensing value is highest in liposome technology, sterile manufacturing, packaging, and protected formulation platforms.

FAQs About Irinotecan Hydrochloride Excipient Commercialization

Can sorbitol be removed from an irinotecan hydrochloride formulation?

Yes, but removal would require a replacement tonicity and stability strategy supported by CMC data. A sorbitol-free formulation would need to demonstrate acceptable pH control, osmolality, degradation profile, container compatibility, and dilution stability.

Is a new irinotecan liposome formulation eligible for 505(b)(2) approval?

Potentially. A liposomal irinotecan product may use a 505(b)(2) pathway when it relies partly on FDA findings for an approved product but introduces a material delivery-system change. The pathway and data requirements depend on the proposed formulation and indication.

Does Onivyde have the same excipients as conventional irinotecan injection?

No. Onivyde uses a liposomal delivery system with lipid components and a sucrose octasulfate-based loading architecture. It is not simply conventional irinotecan injection placed in a different vial.

Are excipient suppliers exposed to irinotecan patent infringement?

Usually, commodity excipient suppliers face less direct risk than finished-product manufacturers. Risk increases when a supplier licenses or manufactures a proprietary excipient combination, liposome component, drug-loading system, or formulation-specific intermediate.

What is the best commercial entry strategy for a new irinotecan product?

For a conventional product, the most practical route is a cost-efficient ANDA with reliable sterile supply and packaging differentiation. For a higher-value opportunity, a 505(b)(2) product using liposomal delivery, extended stability, reduced preparation time, or a protected administration system offers greater differentiation but requires materially higher development investment.

References

1. Pfizer Inc. (2023). Camptosar (irinotecan hydrochloride) injection prescribing information. U.S. Food and Drug Administration.

2. Ipsen Biopharmaceuticals, Inc. (2024). Onivyde (irinotecan liposome injection) prescribing information. U.S. Food and Drug Administration.

3. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs and irinotecan hydrochloride injection product information. https://www.accessdata.fda.gov/scripts/cder/daf/

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book